TIDMOCTP
RNS Number : 0857O
Oxford Cannabinoid Tech.Holdings
29 September 2023
29 September 2023
Oxford Cannabinoid Technologies Holdings plc
("OCTP", or the "Company")
Result of Annual General Meeting
Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP) the
pharmaceutical company developing prescription cannabinoid
medicines, announces that all resolutions set out in the notice of
Annual General Meeting ("AGM") dated 5 September 2023 were passed
at the AGM held at the of ces of Penningtons Manches Cooper LLP,
125 Wood Street, EC2V 7AW on Thursday, 28 September 2023.
Resolution For (including % Against % Total % Withheld*
discretionary) of
ISC
voted
To receive
and adopt
the annual
accounts and
reports of
the Company
and the
auditor's
report
on those
accounts and
reports for
year ended
30 April
1. 2023 317,413,248 98.53 4,742,806 1.47 322,156,054 33.54 196,542
-------------- ------------------ ------ ----- ------ --------------------------------
2. To receive
and approve
the
Directors'
remuneration
report for
year ended
30 April
2023 320,954,970 99.65 1,133,561 0.35 322,088,531 33.54 264,065
-------------- ------------------ ------ ----- ------ --------------------------------
3. To elect Paul
Smalley as a
Director of
the Company 321,217,951 99.71 944,695 0.29 322,162,646 33.54 189,950
-------------- ------------------ ------ ----- ------ --------------------------------
4. To re-elect
Cheryl
Dhillon as
Director of
the Company 317,283,230 98.49 4,879,416 1.51 322,162,646 33.54 189,950
-------------- ------------------ ------ ----- ------ --------------------------------
5. To re-elect
Indraneil
Mahapatra as
Director of
the Company 321,124,133 99.68 1,029,195 0.32 322,153,328 33.54 199,268
-------------- ------------------ ------ ----- ------ --------------------------------
6. To re-appoint
Moore
Kingston
Smith LLP as
auditors of
the Company 321,207,525 99.70 955,121 0.30 322,162,646 33.54 189,950
-------------- ------------------ ------ ----- ------ --------------------------------
7. To authorise
the
Directors to
fix the
remuneration
of the
auditors of
the Company. 321,150,540 99.69 1,010,083 0.31 322,160,623 33.54 191,973
-------------- ------------------ ------ ----- ------ --------------------------------
8. Creation of
the Deferred
Shares as a
new class of
shares. 320,514,800 99.59 1,305,323 0.41 321,820,123 33.51 532,473
-------------- ------------------ ------ ----- ------ --------------------------------
9. Subdivision
of the
Company's
issued share
capital. 320,433,836 99.57 1,391,623 0.43 321,825,459 33.51 527,137
-------------- ------------------ ------ ----- ------ --------------------------------
10. To authorise
the
Directors to
allot
ordinary
shares and
relevant
securities,
pursuant to
Section
551 of the
Companies
Act 2006.** 320,642,980 99.65 1,136,643 0.35 321,779,623 33.50 572,973
-------------- ------------------ ------ ----- ------ --------------------------------
11. To authorise
the
Directors to
disapply
pre-emption
rights ** 320,440,908 99.57 1,391,623 0.43 321,832,531 33.51 520,065
-------------- ------------------ ------ ----- ------ --------------------------------
12. That a
general
meeting
other than
an annual
general
meeting may
be called on
not less
than
14 clear
days'
notice. 321,158,929 99.69 1,006,625 0.31 322,165,554 33.54 187,042
-------------- ------------------ ------ ----- ------ --------------------------------
13. Amendment of
Articles to
cater for
Deferred
Shares. 321,094,593 99.68 1,018,053 0.32 322,112,646 33.54 239,950
-------------- ------------------ ------ ----- ------ --------------------------------
The Directors of the Company accept responsibility for the
content of this announcement.
Enquiries:
O xford Cannabinoid Technologies
Holdings plc +44 (0)20 3034 2820
Clarissa Sowemimo-Coker (CEO) clarissa@oxcantech.com
Rob Bennett (Company Secretary) rob@oxcantech.com
Cairn Financial Advisers LLP
Emily Staples +44 (0)20 7213 0897
Jo Turner
Axis Capital Markets Limited +44 (0) 20 7213 0885
Richard Hutchison +44 (0)20 3026 0320
Acuitas Communications 020 3745 0293 / 07799 767676
Simon Nayyar simon.nayyar@acuitascomms.com
Arthur Dingemans arthur.dingemans@acuitascomms.com
About Oxford Cannabinoid Technologies Holdings Plc:
Oxford Cannabinoid Technologies Holdings plc ("OCTP") is the
holding company of Oxford Cannabinoid Technologies Ltd (together
the "Group"), a pharmaceutical Group developing prescription
cannabinoid medicines initially targeting the U$ multi-billion
global pain market.
OCTP currently has a portfolio of four drug development
programmes. Its lead compound, OCT461201, will initially target
neuropathic and visceral pain (including irritable bowel syndrome
("IBS") and chemotherapy induced peripheral neuropathy ("CIPN")),
with Phase I clinical trials, aimed at demonstrating safety and
tolerability. Trial results are expected in Q3 2023. The global
market for CIPN alone is currently forecast to reach US$1.17bn by
2028.
OCTP's drug development pipeline comprises both natural and
synthetic compounds, and includes compounds targeting trigeminal
neuralgia, a severe type of face pain, and cannabinoid derivatives
targeting pain and potentially other therapeutic areas. Having
established an exclusive license agreement with Canopy Growth
Corporation for their entire pharmaceutical cannabinoid derivative
library, OCTP now has a portfolio of almost five hundred
derivatives and intellectual property rights including fourteen
patent families and associated research data.
OCTP has a clearly defined path to commercialisation, revenues
and growth. The Group is developing drug candidates through
clinical trials to gain regulatory approval (FDA/MHRA/EMA) that
will enable medical professionals to prescribe them with
confidence. OCTP's portfolio aims to balance risk, value and time
to market, whilst ensuring market exclusivity around all its key
activities.
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward-looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGUWRUROVUKUUR
(END) Dow Jones Newswires
September 29, 2023 02:00 ET (06:00 GMT)
Oxford Cannabinoid Techn... (LSE:OCTP)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Cannabinoid Techn... (LSE:OCTP)
Historical Stock Chart
From May 2023 to May 2024
